{
    "id": 13002,
    "fullName": "SQSTM1 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "SQSTM1-ALK results from the fusion of SQSTM1 and ALK, and leads to transformation in cultured cells and tumorigenesis in mouse models (PMID: 21134980). SQSTM1-ALK fusions have been identified in large B-cell lymphoma and epithelioid histiocytoma (PMID: 21134980, PMID: 25413595).",
            "references": [
                {
                    "id": 3727,
                    "pubMedId": 21134980,
                    "title": "Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21134980"
                },
                {
                    "id": 5646,
                    "pubMedId": 25413595,
                    "title": "Epithelioid cell histiocytoma of the skin with clonal ALK gene rearrangement resulting in VCL-ALK and SQSTM1-ALK gene fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25413595"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8878,
        "geneSymbol": "SQSTM1",
        "terms": [
            "SQSTM1",
            "A170",
            "DMRV",
            "FTDALS3",
            "NADGP",
            "OSIL",
            "p60",
            "p62",
            "p62B",
            "PDB3",
            "ZIP3"
        ]
    },
    "variant": "SQSTM1 - ALK",
    "createDate": "10/08/2015",
    "updateDate": "04/09/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 8298,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of patient derived non-small cell lung cancer cells harboring ALK G1202R in the context of SQSTM1-ALK in culture (PMID: 26144315).",
            "molecularProfile": {
                "id": 26224,
                "profileName": "SQSTM1 - ALK ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3367,
                    "pubMedId": 26144315,
                    "title": "PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26144315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13165,
            "profileName": "SQSTM1 - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 17578,
                    "name": "ALK Inhibitor",
                    "profileName": "SQSTM1 - ALK"
                }
            ]
        },
        {
            "id": 26224,
            "profileName": "SQSTM1 - ALK ALK G1202R",
            "profileTreatmentApproaches": [
                {
                    "id": 16869,
                    "name": "Lorlatinib",
                    "profileName": "SQSTM1 - ALK ALK G1202R"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}